|Bid||2.65 x 2000|
|Ask||3.15 x 1500|
|Day's Range||2.53 - 2.90|
|52 Week Range||0.38 - 4.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
Ampio Pharmaceuticals Inc (AMEX:AMPE), a US$233.14M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Del ...
Mike Macaluso is the CEO of Ampio Pharmaceuticals Inc (AMEX:AMPE), which has recently grown to a market capitalization of $220.23M. Understanding how CEOs are incentivised to run and grow theirRead More...
ENGLEWOOD, Colo., Jan. 16, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharmaceutical companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017. The discussions also explored whether Ampion™ could provide not only relief of signs and symptoms of osteoarthritis of the knee (OAK) but also be "a disease-modifying drug" for this condition. David Bar-Or, M.D., Ampio's CSO explained: "OAK, over time, causes progressive loss of cartilage in the knee, which is one of the reasons for limited joint function and chronic pain in this condition (although cartilage has no nerve endings, sub chondral bone does).
In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...
ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...
Examining how Ampio Pharmaceuticals Inc (AMEX:AMPE) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...
Case in point: Ampio Pharmaceuticals Inc (NYSE:AMPE), whose shares are jumping nearly 50% in Thursday trading session. The biopharmaceutical company reported that its knee osteoarthritis drug Ampion met its primary endpoint in Phase 3 clinical trial. Specifically, 71% of Ampion treated patients met OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.
ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p
NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...
ENGLEWOOD, Colo., Nov. 30, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the engagement of LaVoieHealthScience for their services in investor and public relations. LaVoieHealthScience, an integrated investor and public relations agency focused on advancing health and science innovations, will be supporting Ampio in their strategic communications with a broad range of audiences including media, healthcare professionals, the investment community and others. LaVoieHealthScience will use their 16 years of proven industry tactics to help Ampio extend visibility and optimize value.
NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat ...
The article describes the efficacy and safety of Ampion™ (LMWF-5A) in an integrated analysis of three single injection randomized controlled studies of severe osteoarthritis of the knee (Kellgren-Lawrence [KL] grade 4 disease).
ENGLEWOOD, Colo., Nov. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio" or the "Company") today announced the receipt of notification that the Company's plan to regain compliance with the NYSE American's continued listing standards has been accepted by the NYSE American LLC ("NYSE American"). As previously reported by the Company in a Current Report on Form 8-K on September 7, 2017, the Company received a letter from the NYSE American on September 1, 2017 stating that the Company was not in compliance with the continued listing standards of the NYSE American Company Guide (the "Company Guide") relating to stockholders' equity.
ENGLEWOOD, Colo., Nov. 15, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the beginning of an Open Label Extension (OLE) study of Ampion™ in patients with severe osteoarthritis of the knee (OAK). The OLE study offers patients an opportunity to receive repeat injections of Ampion™ after they have completed the pivotal clinical trial. Ampion™ is the low molecular weight fraction of pharmaceutical 5% human serum albumin (HSA).
ENGLEWOOD, Colo., Oct. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio") today announced that it has closed it's previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75 million. The sale of the common stock was offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement was filed with the SEC and forms a part of the effective registration statement.
ENGLEWOOD, Colo., Oct. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.75 million of shares of common stock at a purchase price of $0.875 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial. Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. are acting as placement agents for the offering.
NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Shares of both Ampio Pharmaceuticals (NYSE American: AMPE ) and Ardelyx Inc. (NASDAQ: ARDX ) soared on Thursday after both companies had data news, respectively. ...
ENGLEWOOD, Colo., Oct. 12, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "LMWF-5A For The Treatment Of Severe Osteoarthritis Of The Knee: Integrated Analysis Of Safety And Efficacy" was accepted for publication in Orthopedics, an international peer-reviewed journal in the field of Orthopedics. Ampion™ is the Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A). Ampio's Chief Scientific Officer, Dr. David Bar-Or described the study as follows: "This was a combined analysis of all completed single-injection Ampion™ randomized placebo-controlled trials to date, focusing on the subset of patients with severe (Kellgren-Lawrence [KL] grade 4) osteoarthritis of the knee (OAK).
ENGLEWOOD, Colo., Sept. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the completion of enrollment and dosing of patients in their pivotal single injection study on the "unmet medical need" of severe osteoarthritis of the knee (OAK). These patients experience not only pain but also the loss of function and diminished quality of life. The primary endpoint of this pivotal trial follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) OMERACT-OARSI responder rate to address the signs and symptoms of severe OAK. Michael Macaluso, Ampio's CEO, noted, "Announcing the close of enrollment so quickly speaks to the unmet medical need.
ENGLEWOOD, Colo. , Sept. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...